Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as High Grade Neuroendocrine Carcinomas, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile C...
Phase 2 Recruiting
60 enrolled
SEZanne
Phase 2 Recruiting
180 enrolled
Atezolizumab and Cabozantinib for the Treatment of Adolescents and Young Adults With Recurrent or Metastatic Osteosarcoma, TACOS Study
Phase 2 Recruiting
40 enrolled
Testing Atezolizumab With Selinexor in People ≥ 12 Years Old With Alveolar Soft Part Sarcoma, The AXIOM Trial
Phase 2 Recruiting
27 enrolled
IMCODE003
Phase 2 Recruiting
260 enrolled
A Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruquintinib as a New Treatment for Colorectal Cancer.
Phase 2 Recruiting
90 enrolled
Phase II Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer
Phase 2 Recruiting
35 enrolled
Temozolomide and Atezolizumab for Subsequent Line for the Treatment of Metastatic or Recurrent Small Cell Lung Cancer
Phase 2 Recruiting
56 enrolled
Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer
Phase 2 Recruiting
65 enrolled
A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)
Phase 2 Recruiting
99 enrolled
Kirros
Phase 2 Recruiting
30 enrolled
TAPUR
Phase 2 Recruiting
4,200 enrolled
Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC
Phase 2 Recruiting
60 enrolled
TERTIO
Phase 2 Recruiting
105 enrolled
SBRT With Immunotherapy and Atezo-Bev in HCC With Major Portal Vein Thrombosis
Phase 2 Recruiting
40 enrolled
Phase 2 Trial of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab in Patients With Newly Diagnosed PD-L1 CPS Positive Resectable Stage 3-4 Oral Cavity Squamous Cell Carcinoma (OCSCC).
Phase 2 Recruiting
29 enrolled
Clinical Trial for Safety and Effectiveness Evaluation of Tarlatamab (AMG757) With Etoposide, Carboplatin and Atezolizumab in Transformed Small Cell Lung Cancer Patients From Adenocarcinoma After EGFR TKI Treatment
Phase 2 Recruiting
50 enrolled
Diclofenac for the Treatment of Patients With Metastatic Non-small Cell Lung Cancer on Single Agent Immunotherapy
Phase 2 Recruiting
20 enrolled
ATEZOGIST
Phase 2 Recruiting
110 enrolled
Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation
Phase 2 Recruiting
70 enrolled
AZALEA
Phase 2 Recruiting
45 enrolled
Lamivudine in Combination With Chemoimmunotherapy for the Treatment of Extensive Stage Small Cell Lung Cancer
Phase 2 Recruiting
28 enrolled
ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC
Phase 2 Recruiting
300 enrolled
Vismodegib Combined With Atezolizumab in Platinum Resistant Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
Phase 2 Recruiting
48 enrolled
ATTACH
Phase 2 Recruiting
30 enrolled
SATURN-STS: Phase II Study of Neoadjuvant Atezolizumab With Doxorubicin, Concurrent Atezolizumab With Pre-operative Radiation Therapy and Adjuvant Atezolizumab in Patients With High-risk Surgically Resectable Extremity and Truncal Soft Tissue Sarcoma
Phase 2 Recruiting
50 enrolled
ATHENEA
Phase 2 Recruiting
97 enrolled
ABACUS-2
Phase 2 Recruiting
58 enrolled
MOAB
Phase 2 Recruiting
80 enrolled
(HCC)
Phase 2 Recruiting
19 enrolled
STRATUM
Phase 2 Recruiting
100 enrolled
AB-LATE02
Phase 2 Recruiting
202 enrolled
VIRO-25
Phase 2 Recruiting
142 enrolled
Systemic Chemotherapy With FOLFOX Plus Atezolizumab & Bevacizumab for Patients With Advanced HCC Who Previously Received Atezolizumab & Bevacizumab
Phase 2 Recruiting
30 enrolled
CAPTIV-8
Phase 2 Recruiting
200 enrolled
Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer
Phase 2 Recruiting
122 enrolled
Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)
Phase 2 Recruiting
40 enrolled
FLORA
Phase 2 Recruiting
48 enrolled
ProTarget
Phase 2 Recruiting
300 enrolled
Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer
Phase 2 Recruiting
63 enrolled
NICER
Phase 2 Recruiting
28 enrolled
Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy
Phase 2 Recruiting
68 enrolled
PhotonAB
Phase 2 Recruiting
45 enrolled
Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial
Phase 2 Recruiting
33 enrolled
METEORITE
Phase 2 Recruiting
18 enrolled
TIRACAN
Phase 2 Recruiting
97 enrolled
Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNITION-GUIDE)
Phase 2 Recruiting
240 enrolled
CARRY-ON
Phase 2 Recruiting
142 enrolled
ALERT-HCC
Phase 2 Recruiting
138 enrolled
Stereosarc
Phase 2 Recruiting
103 enrolled